SARS‐COV‐2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications

Solid organ transplant patients are at a higher risk for poor CoronaVirus Disease‐2019 (COVID‐19)‐related outcomes and have been included as a priority group in the vaccination strategy worldwide. We assessed the safety and efficacy of a two‐dose vaccination cycle with mRNA‐based COVID‐19 vaccine (B...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Transplantation 2022-01, Vol.36 (1), p.e14495-n/a
Main Authors: Russo, Gianluca, Lai, Quirino, Poli, Luca, Perrone, Maria Paola, Gaeta, Aurelia, Rossi, Massimo, Mastroianni, Claudio M., Garofalo, Manuela, Pretagostini, Renzo
Format: Article
Language:English
Subjects:
Antibodies, Viral
BNT162 Vaccine
BNT162b2 vaccine
COVID-19
COVID-19 Vaccines
graft rejection
HLA‐DSA
Humans
Kidney Transplantation
Middle Aged
Original
Risk Factors
SARS-CoV-2
Seroepidemiologic Studies
solid organ transplant patients
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid organ transplant patients are at a higher risk for poor CoronaVirus Disease‐2019 (COVID‐19)‐related outcomes and have been included as a priority group in the vaccination strategy worldwide. We assessed the safety and efficacy of a two‐dose vaccination cycle with mRNA‐based COVID‐19 vaccine (BNT162b2) among 82 kidney transplant outpatients followed in our center in Rome, Italy. After a median of 43 post‐vaccine days, a SARS‐CoV‐2 anti‐Spike seroprevalence of 52.4% (n = 43/82) was observed. No impact of the vaccination on antibody‐mediated rejection or graft function was observed, and no significant safety concerns were reported. Moreover, no de novo HLA‐donor‐specific antibodies (DSA) were detected during the follow‐up period. Only one patient with pre‐vaccination HLA‐DSA did not experience an increased intensity of the existing HLA‐DSA. During the follow‐up, only one infection (mild COVID‐19) was observed in a patient after receiving the first vaccine dose. According to the multivariable logistic regression analysis, lack of seroconversion after two‐dose vaccination independently associated with patient age ≥60 years (OR = 4.50; P = .02) and use of anti‐metabolite as an immunosuppressant drug (OR = 5.26; P = .004). Among younger patients not taking anti‐metabolites, the seroconversion rate was high (92.9%). Further larger studies are needed to assess the best COVID‐19 vaccination strategy in transplanted patients.
ISSN:0902-0063
1399-0012
1399-0012
DOI:10.1111/ctr.14495